Early Adoption of Anti–SARS-CoV-2 Pharmacotherapies Among US Veterans With Mild to Moderate COVID-19, January and February 2022

IMPORTANCE: Older adults and individuals with medical comorbidities are at increased risk for severe COVID-19. Several pharmacotherapies demonstrated to reduce the risk of COVID-19–related hospitalization and death have been authorized for use. OBJECTIVE: To describe factors associated with receipt...

Descripción completa

Detalles Bibliográficos
Autores principales: Bajema, Kristina L., Wang, Xiao Qing, Hynes, Denise M., Rowneki, Mazhgan, Hickok, Alex, Cunningham, Francesca, Bohnert, Amy, Boyko, Edward J., Iwashyna, Theodore J., Maciejewski, Matthew L., Viglianti, Elizabeth M., Streja, Elani, Yan, Lei, Aslan, Mihaela, Huang, Grant D., Ioannou, George N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9652752/
https://www.ncbi.nlm.nih.gov/pubmed/36367727
http://dx.doi.org/10.1001/jamanetworkopen.2022.41434

Ejemplares similares

Ejemplares similares